These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12186341)

  • 41. Controversies regarding hormone therapy: Insights from inflammation and hemostasis.
    Koh KK; Yoon BK
    Cardiovasc Res; 2006 Apr; 70(1):22-30. PubMed ID: 16412400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women.
    Sezer Ozer K; Erenus M; Yoldemir T
    Climacteric; 2009 Feb; 12(1):66-71. PubMed ID: 19012050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
    Neves-E-Castro M
    Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
    Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
    Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels--an association with mammographic density.
    Hofling M; Carlström K; Svane G; Azavedo E; Kloosterboer H; Von Schoultz B
    Gynecol Endocrinol; 2005 Feb; 20(2):110-5. PubMed ID: 15823831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator.
    Campisi R; Marengo FD
    Cardiovasc Drug Rev; 2007; 25(2):132-45. PubMed ID: 17614936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of hormonal replacement therapy on breast density in postmenopausal women].
    Bisanti T; Cavalieri AP; Capri O; Galoppi P; De Felice C; Porfiri LM; Perrone G
    Minerva Ginecol; 2004 Apr; 56(2):125-30. PubMed ID: 15258540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bleeding with menopausal hormone therapy.
    Hickey M; Agarwal S
    Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):141-9. PubMed ID: 18977184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tibolone: example of qualitative and quantitative assessments of the mammary gland.
    Cline JM
    Birth Defects Res B Dev Reprod Toxicol; 2007 Apr; 80(2):147-8. PubMed ID: 17443694
    [No Abstract]   [Full Text] [Related]  

  • 53. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study.
    Somunkiran A; Erel CT; Demirci F; Senturk ML
    Maturitas; 2007 Jan; 56(1):61-8. PubMed ID: 16831525
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
    Ozcagli E; Sardas S; Biri A
    Maturitas; 2005 Jul; 51(3):280-5. PubMed ID: 15978971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause.
    Somunkiran A; Yazici B; Demirci F; Erdogmus B; Ozdemir I
    Climacteric; 2006 Feb; 9(1):59-65. PubMed ID: 16428126
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
    Nijland EA; Weijmar Schultz WC; Davis SR
    Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrastructure study of postmenopausal endometria of tibolone, conjugated estrogen + medroxyprogesterone acetate and tamoxifen users.
    Nas T; Sargon MF; Celik HH; Keskin PO; Gürsoy RH; Biberoglu K
    Saudi Med J; 2007 Dec; 28(12):1917-9. PubMed ID: 18060233
    [No Abstract]   [Full Text] [Related]  

  • 58. Tibolone and breast cancer risk: effects of selection bias cannot be eliminated in observational studies.
    Coomarasamy A
    BJOG; 2008 Jun; 115(7):919. PubMed ID: 18485174
    [No Abstract]   [Full Text] [Related]  

  • 59. The drug scene.
    Rowe T
    J Obstet Gynaecol Can; 2014 Oct; 36(10):857-858. PubMed ID: 25375294
    [No Abstract]   [Full Text] [Related]  

  • 60. [Insulin obesity].
    de Paula A
    Rev Bras Med; 1969 Apr; 26(4):217-20. PubMed ID: 5800212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.